Patiromer for Treatment of Hyperkalaemia in Children From Birth to <6 Years of Age

• Status: Not yet recruiting
• Trial end date: 2025-09-30
• Target enrollment: 0
• Participant gender: All

Summary

A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 6 years of age with hyperkalaemia

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vifor Pharma, Inc.

Criteria

Inclusion Criteria:

The following inclusion criteria must be met for each subject:

• Paediatric subjects (<6 years of age) with hyperkalaemia at screening.

• Subject's age should not reach 6 years during the 28 days of the pharmacodynamic (PD)/dose-ranging period.

• Subject is able to receive regular external feeding and medication, including via tubes, e.g., percutaneous endoscopic gastrostomy (PEG).

• If taking any renin-angiotensin aldosterone system inhibitors (RAASi), beta blockers, fludrocortisone, or diuretic medications, must be on a stable dose for at least 14 days prior to screening.

• Parent(s) or legally authorised representative(s) or another appropriate person delegated by the legally authorised representatives must be available to help the study-site personnel ensure follow-up; accompany the participant to the study site on each assessment day; accurately and reliably dispense investigational product as directed.

Exclusion Criteria:

The following criteria exclude a subject from participating in this trial:

• Preterm birth infants with <37 weeks of gestation cannot be included in Cohort B.

• Participants who due to their general condition, e.g., anaemia or low body weight, are not suitable to have blood volume withdrawn.

• Any of the following renal conditions: maintenance haemodialysis or peritoneal dialysis, renal artery stenosis, and acute kidney injury (defined by 2012 Kidney Disease Improving Global Outcomes) or a history of acute renal insufficiency in the past 3 months. Note: Chronic kidney disease (CKD) is not excluded.

• A history of or current diagnosis of a severe gastrointestinal (GI) diagnosis or surgery that could affect GI transit of the drug (delayed gastric emptying), such as a severe swallowing disorder, severe gastroesophageal reflux, uncorrected pyloric stenosis, intussusception, any other intestinal obstruction (e.g., Hirschsprung disease, chronic intestinal pseudo-obstruction, clinically significant postsurgical abdominal adhesions) or any gut-shortening surgical procedure prior to screening. Pre-gastric above-mentioned pathologies may be disregarded in case of existence of a PEG tube, as the PEG tube will serve for nutrition and investigational product administration.

• Active cancer, currently on cancer treatment, or history of cancer in the past 2 years (except for non-melanoma skin cancer).

• Recipient of any organ transplant requiring treatment with immunosuppressive therapy or scheduled for kidney transplant procedure during the first 28 days after Day 1.

• History of sudden infant death in a sibling.

• Use of the following medications if doses have not been stable for at least 14 days prior to screening or if doses are anticipated to change during the 4-week PD/ dose-ranging period: digoxin, bronchodilators, theophylline, heparins (including low molecular heparins), tacrolimus, mycophenolate mofetil, cyclosporine, trimethoprim, or cotrimoxazole.

• Use of any investigational product for an unapproved indication within 30 days prior to screening or within 5 half-lives, whichever is longer.

• Known hypersensitivity to patiromer or its components.

• If the child is being breastfed:

1. There is suspicion of current alcohol or substance misuse/abuse in breastfeeding mother

2. The breastfeeding mother is taking potassium supplements

Other protocol defined Inclusion/Exclusion criteria may apply